A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus

Dag Stockeld; Jan Tennvall; Gunnar Wagenius; Maria Albertsson; Lars Backman; Ola Brodin; Magdalena Cwikiel; Lars Granstrom; Gunnar Gustafsson; Sven Gustavsson; Göran Hambraeus; Rolf Lewensohn; Svante Sjöstedt; Hans Strander; Bengt Aberg; Jan Fagerberg

doi:10.1080/028418601750444097

A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus

Dag Stockeld, Jan Tennvall, Gunnar Wagenius, Maria Albertsson, Lars Backman, Ola Brodin, Magdalena Cwikiel, Lars Granstrom, Gunnar Gustafsson, Sven Gustavsson, Göran Hambraeus, Rolf Lewensohn, Svante Sjöstedt, Hans Strander, Bengt Aberg, Jan Fagerberg

Breastcancer-genetics

Research output: Contribution to journal › Article › peer-review

Abstract

This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion of patients (13/23 [57%] before changes of treatment compared with 30/36 [83%] after changes). Treatment-related mortality was 3.75% (3 patients, associated with leucopenic septicemia after chemotherapy). Fifty-four patients were resected. No per- or postoperative mortality was encountered. The complete response (pathological CR) rate in operated patients was 46% (27/59 patients) after chemoradiation. In the whole series the CR rate (including clinical CR for non-resected patients) was 44%. With a minimum follow-up of 37 months, the 3-year survival for the whole group was 31% compared with 57% for the CR patients. Total 5-year survival thus far (July 1999) is 26%.

Original language	English
Pages (from-to)	566-573
Journal	Acta Oncologica
Volume	40
Issue number	5
DOIs	https://doi.org/10.1080/028418601750444097
Publication status	Published - 2001

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/028418601750444097

Cite this

Stockeld, D., Tennvall, J., Wagenius, G., Albertsson, M., Backman, L., Brodin, O., Cwikiel, M., Granstrom, L., Gustafsson, G., Gustavsson, S., Hambraeus, G., Lewensohn, R., Sjöstedt, S., Strander, H., Aberg, B., & Fagerberg, J. (2001). A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncologica, 40(5), 566-573. https://doi.org/10.1080/028418601750444097

@article{a163f61aba3e433e99f3e1adf6dd56e5,

title = "A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus",

abstract = "This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion of patients (13/23 [57%] before changes of treatment compared with 30/36 [83%] after changes). Treatment-related mortality was 3.75% (3 patients, associated with leucopenic septicemia after chemotherapy). Fifty-four patients were resected. No per- or postoperative mortality was encountered. The complete response (pathological CR) rate in operated patients was 46% (27/59 patients) after chemoradiation. In the whole series the CR rate (including clinical CR for non-resected patients) was 44%. With a minimum follow-up of 37 months, the 3-year survival for the whole group was 31% compared with 57% for the CR patients. Total 5-year survival thus far (July 1999) is 26%.",

author = "Dag Stockeld and Jan Tennvall and Gunnar Wagenius and Maria Albertsson and Lars Backman and Ola Brodin and Magdalena Cwikiel and Lars Granstrom and Gunnar Gustafsson and Sven Gustavsson and G{\"o}ran Hambraeus and Rolf Lewensohn and Svante Sj{\"o}stedt and Hans Strander and Bengt Aberg and Jan Fagerberg",

year = "2001",

doi = "10.1080/028418601750444097",

language = "English",

volume = "40",

pages = "566--573",

journal = "Acta Oncologica",

issn = "1651-226X",

publisher = "Taylor & Francis",

number = "5",

}

Stockeld, D, Tennvall, J, Wagenius, G, Albertsson, M, Backman, L, Brodin, O, Cwikiel, M, Granstrom, L, Gustafsson, G, Gustavsson, S, Hambraeus, G, Lewensohn, R, Sjöstedt, S, Strander, H, Aberg, B & Fagerberg, J 2001, 'A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus', Acta Oncologica, vol. 40, no. 5, pp. 566-573. https://doi.org/10.1080/028418601750444097

TY - JOUR

T1 - A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus

AU - Stockeld, Dag

AU - Tennvall, Jan

AU - Wagenius, Gunnar

AU - Albertsson, Maria

AU - Backman, Lars

AU - Brodin, Ola

AU - Cwikiel, Magdalena

AU - Granstrom, Lars

AU - Gustafsson, Gunnar

AU - Gustavsson, Sven

AU - Hambraeus, Göran

AU - Lewensohn, Rolf

AU - Sjöstedt, Svante

AU - Strander, Hans

AU - Aberg, Bengt

AU - Fagerberg, Jan

PY - 2001

Y1 - 2001

N2 - This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion of patients (13/23 [57%] before changes of treatment compared with 30/36 [83%] after changes). Treatment-related mortality was 3.75% (3 patients, associated with leucopenic septicemia after chemotherapy). Fifty-four patients were resected. No per- or postoperative mortality was encountered. The complete response (pathological CR) rate in operated patients was 46% (27/59 patients) after chemoradiation. In the whole series the CR rate (including clinical CR for non-resected patients) was 44%. With a minimum follow-up of 37 months, the 3-year survival for the whole group was 31% compared with 57% for the CR patients. Total 5-year survival thus far (July 1999) is 26%.

AB - This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion of patients (13/23 [57%] before changes of treatment compared with 30/36 [83%] after changes). Treatment-related mortality was 3.75% (3 patients, associated with leucopenic septicemia after chemotherapy). Fifty-four patients were resected. No per- or postoperative mortality was encountered. The complete response (pathological CR) rate in operated patients was 46% (27/59 patients) after chemoradiation. In the whole series the CR rate (including clinical CR for non-resected patients) was 44%. With a minimum follow-up of 37 months, the 3-year survival for the whole group was 31% compared with 57% for the CR patients. Total 5-year survival thus far (July 1999) is 26%.

U2 - 10.1080/028418601750444097

DO - 10.1080/028418601750444097

M3 - Article

SN - 1651-226X

VL - 40

SP - 566

EP - 573

JO - Acta Oncologica

JF - Acta Oncologica

IS - 5

ER -

A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this